On April 26, 2026, the Company entered into a definitive agreement to sell its PRV that was originally issued in connection with the FDA’s approval of the BLA for KRESLADI™ for $180 million. The Company announced the closing of the transaction on June 12, 2026, and the Company recognized a net gain of $178.2 million related to the sale.